Key facts
- OncoPrecision’s last known valuation is $18.0M (Oct 2025).
- It has raised $8.7M; the latest was Seed Round ($4.5M) in Oct 2025.
- Notable investors include SOSV, Endless Frontier Labs, IndieBio, New York Ventures, Creative Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for OncoPrecision
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoPrecision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoPrecision
Developer of a patient micro avatar platform designed to get the cancer therapy to the right patient. The company's platform leverages single-cell high-throughput biology machine learning to provide comprehensive patient-derived phenotypic biomarkers to tailor cancer therapy across modalities and dramatically improve patient success, enabling oncologists to make data-driven decisions based on patient-derived samples.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 25
- Website
- oncoprecision.bio/
- Ownership
- Privately Held (backing)
OncoPrecision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoPrecision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoPrecision in its N-PORT filings yet. We sweep new filings monthly.